Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience

Maria Grazia Cusi, Edoardo Conticini, Claudia Gandolfo, Gabriele Anichini, Gianni Gori Savellini, Serafina Valente, Federico Franchi, Sabino Scolletta, Elena Percivalle, Bruno Frediani

Research output: Contribution to journalArticlepeer-review


Background: Convalescent plasma (CP) and hyperimmune plasma (HP) are passive immunotherapies consisting in the infusion of plasma from recovered people into infected patients. Following pre-existing evidence in many other viral diseases, such as SARS, MERS and Ebola, CP and HP have also been proposed for the treatment of COVID-19. Nevertheless, due to the lack of large, well-designed, clinical trials, no clear-cut guidelines exist about what subtype of patient CP and HP should be administered to. Case presentation: We have reported the cases of 3 patients, all immunosuppressed and affected by non-severe, prolonged COVID-19. They were treated with HP, whose neutralizing titer was higher than 1/80. The first patient was a 55-year-old male, who had undergone lung transplant. He was under therapy with Tacrolimus and developed non-neutralizing antibodies against SARS-CoV2. The second patient was a 77-year-old female, affected by follicular lymphoma. She had tested positive for SARS-CoV2 after 6 months. The third was a 60-year-old patient, affected by chronic leukemia. He did not develop antibodies after 2-month disease. All 3 patients received HP and had tested negative for SARS-CoV2 within 2 weeks. Conclusion: Despite encouraging initial data, no strong evidence exist in support of CP and HP to treat COVID-19. In our experience, although limited due to the reduced number of patients, we found a good safety and efficacy of HP in 3 immuno-deficient subjects. Further data are needed in order to assess whether this subtype of patients may particularly benefit from passive immunization.

Original languageEnglish
Article number630
JournalBMC Infectious Diseases
Issue number1
Publication statusPublished - Dec 2021


  • Convalescent plasma
  • COVID-19
  • Hyperimmune plasma
  • Immunodeficiency
  • SARS-CoV2

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience'. Together they form a unique fingerprint.

Cite this